The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market, with the U.S. expected to grow from USD 3.16 billion to USD 8.17 billion by 2035.

The global perfusion systems market is projected to grow from USD 1.5 billion in 2025 to USD 2.4 billion by 2034 at a CAGR of ~5%, driven by increasing cardiovascular disorders, rising organ transplantation procedures, technological innovations, and an aging population. North America leads the market with 41% share. Recent FDA clearances for advanced perfusion devices signal continued innovation in the sector.

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.

The global neuromodulation devices market is projected to grow from USD 7.8 billion in 2024 to USD 16.1 billion by 2032, driven by increasing prevalence of chronic neurological conditions, technological innovations, and supportive regulatory frameworks. North America leads with 55% market share, while Asia-Pacific emerges as the fastest-growing region with over 12% CAGR. Recent FDA approvals include ProlivRx for depression treatment and Medtronic's adaptive deep brain stimulation system for Parkinson's disease.

VivaNova, backed by Lumos Robotics, officially launched its Viva Series of active ergonomic chairs at imm cologne 2026 and announced the Nova Series—the world's first AI-powered smart chair coming in June 2026. The brand integrates humanoid robot technology into furniture, featuring intelligent motion systems, sensory capabilities, and adaptive support designed to provide proactive health care rather than passive support.

The global ECMO machine market is projected to grow from USD 495 million in 2025 to USD 725.99 million by 2033 at a CAGR of 4.91%, driven by rising respiratory and cardiac conditions and expanding critical care infrastructure. However, high costs, complex operations, and regulatory challenges pose barriers to market expansion. North America leads with 44.17% market share, while Asia Pacific is the fastest-growing region.

The global magnetic ablation catheters market is expected to grow significantly, reaching $1.1 billion by 2035, driven by advancements in technology and the rising prevalence of cardiovascular diseases. Key factors driving growth include the increasing adoption of minimally invasive procedures and continued investment in healthcare infrastructure and R&D.

The cardiac resynchronization therapy market is expected to grow at a CAGR of 6.49% from 2024 to 2030, driven by increasing cardiovascular disorders, innovative product developments, and the rising geriatric population. North America is expected to dominate the market during the forecast period.

The global blood recovery machine market is expected to grow at a CAGR of 5.9% from 2024 to 2033, driven by advancements in medical technologies, increased awareness of autologous blood transfusion benefits, and rising demand for surgical procedures.

The global electrotherapy system market is expected to grow from $1.15 billion in 2023 to $1.65 billion by 2030, driven by advancements in technology and increasing demand for non-invasive treatment options. The TENS segment dominates the market, particularly for chronic pain management.

The report provides a comprehensive analysis of the United States cardiovascular surgery devices market, focusing on beating heart surgery systems and perfusion disposables. It includes market revenue, volume, and average prices from 2018 to 2033, as well as company share and distribution data for 2023.

CMR Surgical, a global surgical robotics company, has appointed Daniel Moore as its new Non-Executive Chairman. Moore brings over 35 years of senior leadership experience in the medical technology industry, including roles at Boston Scientific and LivaNova.